Search Results
Search for other papers by C Ratineau in
Google Scholar
PubMed
Search for other papers by C Roche in
Google Scholar
PubMed
Search for other papers by F Chuzel in
Google Scholar
PubMed
Search for other papers by M Cordier-Bussat in
Google Scholar
PubMed
Search for other papers by M Blanc in
Google Scholar
PubMed
Search for other papers by C Bernard in
Google Scholar
PubMed
Search for other papers by J-C Cuber in
Google Scholar
PubMed
Search for other papers by J-A Chayvialle in
Google Scholar
PubMed
Abstract
The effect of glucocorticoids on the expression of intestinal cholecystokinin (CCK) was investigated both in vivo and in cell culture systems. In vivo, 2-day administration of methylprednisolone to adult male rats induced a decrease in CCK-like immunoreactivity (CCK-LI) and CCK mRNA levels in mucosal extracts. In two CCK-producing cell lines, RIN 1056E and STC-1 of pancreatic and intestinal origin respectively, dexamethasone induced dose-dependent decreases in both CCK-LI and steady-state CCK mRNA levels. The decrease in CCK mRNA was totally prevented by incubation of cells with an excess of RU 38486, a competitive inhibitor for the binding of glucocorticoids to their receptor. Actinomycin D, used to prevent RNA synthesis, did not modify CCK mRNA stability in dexamethasone-pretreated cells as compared with cells not exposed to dexamethasone. When cells were first incubated with actinomycin D, subsequent addition of dexamethasone left the steady-state CCK mRNA levels unaltered in both cell lines. Nuclear run-on assays performed in RIN 1056E cells showed that glucocorticoids decreased the rate of transcription of the CCK gene. In addition, cycloheximide, used to prevent protein synthesis, abolished the inhibitory effects of dexamethasone on steady-state CCK mRNA levels. These results demonstrate that glucocorticoids down-regulate CCK gene expression in the rat intestinal mucosa and in two CCK-producing cell lines. The effect is blocked by a glucocorticoid receptor antagonist. Inhibition of CCK gene expression may result from a decrease in the transcription rate, and probably involves one or several steps that depend on protein synthesis.
Journal of Endocrinology (1996) 151, 137–145
Search for other papers by T Takeda in
Google Scholar
PubMed
Search for other papers by H Kurachi in
Google Scholar
PubMed
Search for other papers by T Yamamoto in
Google Scholar
PubMed
Search for other papers by Y Nishio in
Google Scholar
PubMed
Search for other papers by Y Nakatsuji in
Google Scholar
PubMed
Search for other papers by K Morishige in
Google Scholar
PubMed
Search for other papers by A Miyake in
Google Scholar
PubMed
Search for other papers by Y Murata in
Google Scholar
PubMed
Cytokines and steroid hormones use different sets of signal transduction pathways, which seem to be unrelated. Interleukin-6 (IL-6) uses JAK tyrosine kinase and STAT (signal transducer and activator of transcription) transcription factor. Glucocorticoid binds glucocorticoid receptor (GR), which is a member of the steroid receptor superfamily. We have studied the crosstalk between the IL-6-JAK-STAT and glucocorticoid-nuclear receptor pathways. IL-6 and glucocorticoid synergistically activated the IL-6 response element on the rat alpha2-macroglobulin promoter (APRE)-driven luciferase gene. The exogenous expression of GR enhanced the synergism. The exogenous expression of dominant negative STAT3 completely abolished the IL-6 plus glucocorticoid-induced activation of the APRE-luciferase gene. Tyrosine phosphorylation of STAT3 stimulated by IL-6 alone was not different from that by IL-6 plus glucocorticoid. The protein level of STAT3 was also not increased by glucocorticoid stimulation. The time course of STAT3 tyrosine phosphorylation by IL-6 plus glucocorticoid was not different from that by IL-6 alone. The synergism was studied on the two other IL-6 response elements, the junB promoter (JRE-IL-6) and the interferon regulatory factor-1 (IRF-1) promoter (IRF-GAS) which could be activated by STAT3. The synergistic activation by glucocorticoid on the IL-6-activated JRE-IL-6 and the IRF-GAS-driven luciferase gene was not detected. Glucocorticoid did not change the mobility of IL-6-induced APRE-binding proteins in a gel shift assay. These results suggest that the synergism was through the GR and STAT3, and the coactivation pathway which was specific for APRE was the target of glucocorticoid.
Department of Microbiology, University of Virginia Health Sciences, PO Box 800734, Charlottesville, Virginia 22908, USA
Search for other papers by P V Gordon in
Google Scholar
PubMed
Department of Microbiology, University of Virginia Health Sciences, PO Box 800734, Charlottesville, Virginia 22908, USA
Search for other papers by J B Paxton in
Google Scholar
PubMed
Department of Microbiology, University of Virginia Health Sciences, PO Box 800734, Charlottesville, Virginia 22908, USA
Search for other papers by N S Fox in
Google Scholar
PubMed
Introduction Glucocorticoids trigger mucosal maturation during weaning and can accelerate the process if given exogenously in the week immediately prior to weaning ( Henning & Sims 1979 , Oesterreicher et al. 1998 , Solomon et
Search for other papers by OC Meijer in
Google Scholar
PubMed
Search for other papers by AM Karssen in
Google Scholar
PubMed
Search for other papers by ER de Kloet in
Google Scholar
PubMed
The biological mechanisms that determine cell-specific responses to glucocorticoid hormones may overlap with those that are associated with acquired glucocorticoid resistance. Cell and tIssue specificity can be brought about in many different ways. Studies on the brain, an important glucocorticoid target tIssue, may provide examples of regulatory mechanisms underlying response specificity at multiple levels. In this commentary a number of such mechanisms are discussed, with emphasis on regulation of glucocorticoid bio-availability by the efflux transporter P-glycoprotein and on the variable presence of nuclear proteins which modulate or interfere with gluco- and mineralocorticoid receptor-mediated transcription.
Search for other papers by M Schmidt in
Google Scholar
PubMed
Search for other papers by C Renner in
Google Scholar
PubMed
Search for other papers by G Loffler in
Google Scholar
PubMed
In fibroblasts derived from human adipose tissue, aromatase induction is observed after exposure to 1 microM cortisol in the presence of serum or platelet-derived growth factor (PDGF). Progesterone suppresses this induction in a dose-dependent manner, 10 microM resulting in complete inhibition. A reduced cortisol concentration (0.1 microM) concomitantly reduces the progesterone concentration required for effective inhibition (10-100 nM). This effect of progesterone is specific, as neither the release of cellular enzymes nor aromatase induction by dibutyryl-cAMP, which acts independently from cortisol, are affected. However, the inhibitory effect of progesterone requires its presence throughout the induction period. Kinetic studies in intact cells reveal a reduced number of aromatase active sites upon progesterone treatment, whereas progesterone at near-physiological concentration (100 nM) does not inhibit aromatase activity in isolated microsomes. Semi-quantitative reverse transcriptase PCR analysis shows reduced amounts of aromatase mRNA in progesterone-treated cells, indicating specific inhibition of the glucocorticoid-dependent pathway of aromatase induction. The inhibitory effect of progesterone is not blocked by the anti-progestin ZK114043, excluding action via progesterone receptors and indicating competition for the glucocorticoid receptor. Progesterone must be considered a potential physiological inhibitor of glucocorticoid-dependent aromatase induction in adipose tissue. It is proposed that it is a suppressor of aromatase induction in adipose tissue in premenopausal women.
Search for other papers by JI Webster in
Google Scholar
PubMed
Search for other papers by EM Sternberg in
Google Scholar
PubMed
The hypothalamic-pituitary-adrenal (HPA) axis is activated during many bacterial and viral infections, resulting in an increase in circulating glucocorticoid levels. This HPA axis activation and glucocorticoid response are critical for the survival of the host, as demonstrated by the fact that removal of the HPA axis (by adrenalectomy or hypophysectomy) or glucocorticoid receptor (GR) blockade enhances the severity of the infection and in some cases enhances the mortality rate. Replacement with a synthetic glucocorticoid reverses these effects by reducing the severity of the infection and provides protection against lethal effects. In addition, some bacteria and viral infections have been shown to affect the GR directly. These have been described and the implications of such an effect discussed.
Search for other papers by I. Audouin in
Google Scholar
PubMed
Search for other papers by H. Garcin in
Google Scholar
PubMed
Search for other papers by I. Pailler-Rodde in
Google Scholar
PubMed
Search for other papers by P. Higueret in
Google Scholar
PubMed
ABSTRACT
The influence of vitamin A on the binding properties of hepatic glucocorticoid receptors (GR) was studied in young rats 7 weeks after they had been given a diet with or without vitamin A. Scatchard analysis showed an increased capacity of cytosolic GRs to bind dexamethasone in vitamin A deficiency. In these rats, an increase in tyrosine aminotransferase also occurred, and this could be related to the increased formation of hormone–GR complexes. Measurement of protein kinase C activity showed an increase which might be related to the functional activity of GRs.
Journal of Endocrinology (1992) 133, 169–173
Search for other papers by PM Jamieson in
Google Scholar
PubMed
Search for other papers by MJ Nyirenda in
Google Scholar
PubMed
Search for other papers by BR Walker in
Google Scholar
PubMed
Search for other papers by KE Chapman in
Google Scholar
PubMed
Search for other papers by Seckl JR in
Google Scholar
PubMed
In vitro, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catalyses the interconversion of active corticosterone and inert 11-dehydrocorticosterone. 11beta-HSD-1 is highly expressed in liver, where the reaction direction is 11beta-reduction, thus potentially increasing intrahepatic active glucocorticoid levels. Inhibition of 11beta-HSD-1 increases insulin sensitivity in humans in vivo suggesting that hepatic 11beta-HSD-1 plays a role in the maintenance or control of key glucocorticoid-regulated metabolic functions. We have selectively repressed hepatic 11beta-HSD-1 in rats by oestradiol administration for 42 days. This nearly completely repressed hepatic 11beta-HSD-1 mRNA expression and enzyme activity and reduced expression of hepatic glucocorticoid-inducible genes including phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting step in gluconeogenesis. Similar effects were seen after 3 weeks of oestradiol treatment. To examine whether this was due to any direct effect of oestradiol upon PEPCK, the experiment was repeated in adrenalectomised rats+/-glucocorticoid replacement. In adrenalectomised rats, oestradiol did not attenuate hepatic PEPCK, whilst glucocorticoid replacement restored this action. Oestradiol did not alter hepatic metabolism of corticosterone by pathways other than 11beta-HSD-1. These data suggest 11beta-HSD-1 plays an important role in maintaining expression of key glucocorticoid-regulated hepatic transcripts. Enzyme inhibition may provide a useful therapeutic target for manipulating glucose homeostasis.
Search for other papers by Mao Li in
Google Scholar
PubMed
Search for other papers by John F Leatherland in
Google Scholar
PubMed
Search for other papers by Matt M Vijayan in
Google Scholar
PubMed
Search for other papers by W Allan King in
Google Scholar
PubMed
Search for other papers by Pavneesh Madan in
Google Scholar
PubMed
whether these very early embryonic responses to cortisol were associated with the interaction of the hormone with glucocorticoid receptors (GRs; Veleiro et al . 2010 ). GRs, together with gr mRNA transcripts, are ubiquitous in the cytosol of post
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
Search for other papers by Claire L Wood in
Google Scholar
PubMed
Search for other papers by Rob van ‘t Hof in
Google Scholar
PubMed
Search for other papers by Scott Dillon in
Google Scholar
PubMed
Search for other papers by Volker Straub in
Google Scholar
PubMed
Search for other papers by Sze C Wong in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Colin Farquharson in
Google Scholar
PubMed
of dystrophin protein weakens the sarcolemmal membrane and results in progressive replacement of muscle fibres by fat and fibrous tissue ( Deconinck & Dan 2007 ). Glucocorticoids (GC) are currently the mainstay of treatment in DMD and are an
